

**REMARKS**

The foregoing amendments are effected to more particularly point out and distinctly define the subject matter of this invention.

**I. CLAIM STATUS & AMENDMENTS**

Claim 1-9 have been restricted.

Claims 1-7 have been amended into method claims. Support can be found in the disclosure, for example, at page 5, lines 1-4, page 17, line 16 to page 18, line 12 and original claims 1-7.

This amendment changes the subject matter of claims 1-7 (i.e., Group I) from an agent to a method of treating by administering said agent. In particular, amended claims 1-7 are directed to a method for treating chondroma and chondrosarcoma, which comprises administering to a subject in need thereof, a substance which inhibits binding of parathyroid hormone related peptide to a receptor thereof. The claims were so amended, because the original claims were drafted in accordance with Japanese practice, which allows a medicament for a second pharmaceutical use. The amended claims accurately reflect the disclosed method of treatment in accordance with US practice.

**II. RESPONSE TO RESTRICTION**

In response to the Restriction Requirement dated March 1, 2007, Applicants hereby elect the invention identified as Group I, as it applies to amended claims 1-7. Since examination on the merits has not begun, it is respectfully requested that the method of amended claims 1-7 be examined on the merits as the elected invention of Group I.


In the event that the Office will not permit amended claims 1-7 to be used as the elected invention of Group I, kindly give Applicants a chance to make an additional election.

Attorney Docket No. 2005\_0714A  
Serial No. 10/533,584  
March 20, 2007

Favorable action on the merits is now requested.

Respectfully submitted,

Hideki YOSHIKAWA et al.

By:   
Jay F. Williams  
Registration No. 48,036  
Attorney for Applicants

JFW/mjw  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
March 20, 2007